Long-term effects of metformin versus sodium glucose transporter 2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes
While Metformin remains effective for glycemic control, SGLT2i offers distinct cardiovascular benefits, notably in reducing the risks of MI and HHF.
Authors
- Xiuxian Hao
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Qingdao Municipal Hospital (CN)
Publication Details
- Journal
- American Journal of Translational Research
- Published
- 2025-01-01
- DOI
- https://doi.org/10.62347/ynwl3428
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00